ALKS » Topics » Our common stock price is highly volatile.

These excerpts taken from the ALKS 10-K filed May 28, 2009.
Our common stock price is highly volatile.
 
The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and adverse effect on the market price of our common stock. Additionally, market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for


33


Table of Contents

reasons that were unrelated to the operating performance of any one company. In particular, and in addition to circumstances described elsewhere under these risk factors, the following risk factors can adversely affect the market price of our common stock:
 
  •  non-approval, set-backs or delays in the development or manufacture of our product candidates and success of our research and development programs;
 
  •  public concern as to the safety of drugs developed by us or others;
 
  •  announcements of issuances of common stock or acquisitions by us;
 
  •  the announcement and timing of new product introductions by us or others;
 
  •  material public announcements;
 
  •  events related to our products or those of our competitors, including the withdrawal or suspension of products from the market;
 
  •  availability and level of third party reimbursement;
 
  •  political developments or proposed legislation in the pharmaceutical or healthcare industry;
 
  •  economic or other external factors, disaster or crisis;
 
  •  developments of our corporate partners;
 
  •  termination or delay of development program(s) by our corporate partners;
 
  •  announcements of technological innovations or new therapeutic products or methods by us or others;
 
  •  changes in government regulations or policies or patent decisions;
 
  •  changes in patent legislation or adverse changes to patent law;
 
  •  changes in key members of management;
 
  •  failure to meet our financial expectations or changes in opinions of analysts who follow our stock; or
 
  •  general market conditions.
 
Our
common stock price is highly volatile.



 



The realization of any of the risks described in these risk
factors or other unforeseen risks could have a dramatic and
adverse effect on the market price of our common stock.
Additionally, market prices for securities of biotechnology and
pharmaceutical companies, including ours, have historically been
very volatile. The market for these securities has from time to
time experienced significant price and volume fluctuations for





33





Table of Contents






reasons that were unrelated to the operating performance of any
one company. In particular, and in addition to circumstances
described elsewhere under these risk factors, the following risk
factors can adversely affect the market price of our common
stock:


 
















































































































































































  • 

non-approval, set-backs or delays in the development or
manufacture of our product candidates and success of our
research and development programs;
 
  • 

public concern as to the safety of drugs developed by us or
others;
 
  • 

announcements of issuances of common stock or acquisitions by us;
 
  • 

the announcement and timing of new product introductions by us
or others;
 
  • 

material public announcements;
 
  • 

events related to our products or those of our competitors,
including the withdrawal or suspension of products from the
market;
 
  • 

availability and level of third party reimbursement;
 
  • 

political developments or proposed legislation in the
pharmaceutical or healthcare industry;
 
  • 

economic or other external factors, disaster or crisis;
 
  • 

developments of our corporate partners;
 
  • 

termination or delay of development program(s) by our corporate
partners;
 
  • 

announcements of technological innovations or new therapeutic
products or methods by us or others;
 
  • 

changes in government regulations or policies or patent
decisions;
 
  • 

changes in patent legislation or adverse changes to patent law;
 
  • 

changes in key members of management;
 
  • 

failure to meet our financial expectations or changes in
opinions of analysts who follow our stock; or
 
  • 

general market conditions.


 




These excerpts taken from the ALKS 10-K filed May 30, 2008.
Our common stock price is highly volatile.
 
The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and adverse effect on the market price of our common stock. Additionally, market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that were unrelated to the operating performance of any one company. In particular, and in addition to circumstances described elsewhere under these risk factors, the following risk factors can adversely affect the market price of our common stock:
 
  •  non-approval, set-backs or delays in the development or manufacture of our product candidates and success of our research and development programs;
 
  •  public concern as to the safety of drugs developed by us or others;
 
  •  announcements of issuances of common stock or acquisitions by us;
 
  •  the announcement and timing of new product introductions by us or others;
 
  •  material public announcements;
 
  •  events related to our products or those of our competitors, including the withdrawal or suspension of products from the market;
 
  •  availability and level of third party reimbursement;
 
  •  political developments or proposed legislation in the pharmaceutical or healthcare industry;
 
  •  economic or other external factors, disaster or crisis;
 
  •  developments of our corporate partners;
 
  •  termination or delay of development program(s) by our corporate partners;
 
  •  announcements of technological innovations or new therapeutic products or methods by us or others;
 
  •  changes in government regulations or policies or patent decisions;
 
  •  changes in patent legislation or adverse changes to patent law;


31


Table of Contents

 
  •  changes in key members of management;
 
  •  failure to meet our financial expectations or changes in opinions of analysts who follow our stock; or
 
  •  general market conditions.
 
Our
common stock price is highly volatile.



 



The realization of any of the risks described in these risk
factors or other unforeseen risks could have a dramatic and
adverse effect on the market price of our common stock.
Additionally, market prices for securities of biotechnology and
pharmaceutical companies, including ours, have historically been
very volatile. The market for these securities has from time to
time experienced significant price and volume fluctuations for
reasons that were unrelated to the operating performance of any
one company. In particular, and in addition to circumstances
described elsewhere under these risk factors, the following risk
factors can adversely affect the market price of our common
stock:


 


















































































































































  • 

non-approval, set-backs or delays in the development or
manufacture of our product candidates and success of our
research and development programs;
 
  • 

public concern as to the safety of drugs developed by us or
others;
 
  • 

announcements of issuances of common stock or acquisitions by us;
 
  • 

the announcement and timing of new product introductions by us
or others;
 
  • 

material public announcements;
 
  • 

events related to our products or those of our competitors,
including the withdrawal or suspension of products from the
market;
 
  • 

availability and level of third party reimbursement;
 
  • 

political developments or proposed legislation in the
pharmaceutical or healthcare industry;
 
  • 

economic or other external factors, disaster or crisis;
 
  • 

developments of our corporate partners;
 
  • 

termination or delay of development program(s) by our corporate
partners;
 
  • 

announcements of technological innovations or new therapeutic
products or methods by us or others;
 
  • 

changes in government regulations or policies or patent
decisions;
 
  • 

changes in patent legislation or adverse changes to patent law;





31





Table of Contents





 




































  • 

changes in key members of management;
 
  • 

failure to meet our financial expectations or changes in
opinions of analysts who follow our stock; or
 
  • 

general market conditions.


 




This excerpt taken from the ALKS 10-K filed Jun 14, 2007.
Our common stock price is highly volatile.
 
The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and adverse effect on the market price of our common stock. Additionally, market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that were unrelated to the operating performance of any one company. In particular, and in addition to circumstances described elsewhere under these risk factors, the following risk factors can adversely affect the market price of our common stock:
 
  •  non-approval, set-backs or delays in the development or manufacture of our product candidates and success of our research and development programs;
 
  •  public concern as to the safety of drugs developed by us or others;
 
  •  announcements of issuances of common stock or acquisitions by us;
 
  •  the announcement and timing of new product introductions by us or others;
 
  •  material public announcements;
 
  •  events related to our products or those of our competitors, including the withdrawal or suspension of products from the market;
 
  •  availability and level of third party reimbursement;
 
  •  political developments or proposed legislation in the pharmaceutical or healthcare industry;
 
  •  economic or other external factors, disaster or crisis;
 
  •  developments of our corporate partners;
 
  •  announcements of technological innovations or new therapeutic products or methods by us or others;
 
  •  changes in government regulations or policies or patent decisions;
 
  •  failure to meet our financial expectations or changes in opinions of analysts who follow our stock; or
 
  •  general market conditions.


30


Table of Contents

 
This excerpt taken from the ALKS 10-K filed Jun 14, 2006.
Our common stock price is highly volatile.
 
The realization of any of the risks described in these risk factors (“Risk Factors”) or other unforeseen risks could have a dramatic and adverse effect on the market price of our common stock. Additionally, market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that were unrelated to the operating performance of any one company. In particular, and in addition to circumstances described elsewhere under these Risk Factors, the following Risk Factors can adversely affect the market price of our common stock:
 
  •  non-approval, set-backs or delays in the development or manufacture of our product candidates and success of our research and development programs;
 
  •  public concern as to the safety of drugs developed by us or others;
 
  •  announcements of issuances of common stock or acquisitions by us;
 
  •  the announcement and timing of new product introductions by us or others;
 
  •  material public announcements;


28


Table of Contents

 
  •  events related to our products or those of our competitors, including the withdrawal or suspension of products from the market;
 
  •  availability and level of third party reimbursement;
 
  •  political developments or proposed legislation in the pharmaceutical or healthcare industry;
 
  •  economic or other external factors, disaster or crisis;
 
  •  developments of our corporate partners;
 
  •  announcements of technological innovations or new therapeutic products or drug delivery methods by us or others;
 
  •  changes in government regulations or policies or patent decisions;
 
  •  failure to meet our financial expectations or changes in opinions of analysts who follow our stock; or
 
  •  general market conditions.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki